- 팍스젠바이오, 중소벤처기업부 주관 ‘글로벌강소기업 1000+ 프로젝트’ 최종 선정 > 뉴스 - 스타트업 커뮤니티 씬디스
- 팍스젠바이오(대표 박영석)가 중소벤처기업부에서 주관하는 2024년 ‘글로벌강소기업 1000+ 프로젝트’에 최종 선정됐다고 3일 밝혔다. 이 …, 스타트업에 종사하시는 여러분들의 놀이터 씬디스는 스타트업 커뮤니티 입니다.
Paxgenbio (CEO Youngseok Park) announced on the 3rd that it has been finally selected for the 2024 'Global Leading Small and Medium-sized Enterprise 1000+ Project' hosted by the Ministry of SMEs and Startups.
This project aims to cultivate export-leading companies by discovering export-oriented SMEs with high growth potential and supporting them in various fields, including marketing and finance. Selected companies receive various benefits, including export support programs, policy finance, guarantees and insurance, preferential interest rates and foreign exchange transaction conditions from commercial banks, R&D projects, and preferential treatment in local government support projects.
A total of 2,080 companies applied for this 'Global Leading Small and Medium-sized Enterprise 1000+ Project', which designates promising SMEs that are advancing into the global market based on excellent technological prowess and innovation, resulting in a 4.4:1 competition ratio. Paxgenbio was finally selected as a promising company.
Paxgenbio is a molecular diagnostics specialist that manufactures and exports in vitro diagnostic medical devices. It utilizes its self-developed 'MPCR-ULFA', the world's first multiplex rapid molecular diagnostic core patent technology, to introduce products that can diagnose respiratory viruses, tuberculosis, sexually transmitted infections, and human papillomavirus more accurately and effectively.
Based on its innovative technologies and products, Paxgenbio has advanced into all continents, including India, Vietnam, Bolivia, the Czech Republic, and Zimbabwe. In particular, in India, it participated in the National Tuberculosis Elimination Program (NTEP) and conducted clinical trials with its Indian partner, AB Company, with the goal of eradicating tuberculosis. It also promoted its products through the 'MICROCON India' exhibition.
Recently, it secured new export contracts for all its product lines to Venezuela, and in Iran, it collaborated with its partner company, FAM TAN AZMA, to promote its products and technologies at the 'Quality Improvement in Clinical Laboratories Congress (QICL 2024)' held in Tehran.
Youngchae Jeon, Managing Director of Overseas Marketing at Paxgenbio, expressed his aspirations, stating, "We anticipate that being selected for the Global Leading Small and Medium-sized Enterprise 1000+ Project will significantly boost our overseas market entry. We will do our utmost to expand overseas sales to achieve Paxgenbio's KOSDAQ listing within two years."
Paxgenbio Introduction
Paxgenbio develops and sells various infectious disease products (sexually transmitted infections, respiratory, tuberculosis, cervical cancer, etc.) based on its core 'MPCR-ULFA platform technology' for multiplex rapid molecular diagnostics. It is also leading a new paradigm in next-generation in vitro diagnostics by developing early cancer diagnostic technologies and building a next-generation multiplex molecular point-of-care platform. Paxgenbio is not content with simply providing medical services to prevent and control infectious diseases. We hope to contribute to solving global health issues through swift, accurate, and affordable services.
Website: http://paxgenbio.com/
Contact
Paxgenbio
Marketing Department
Managing Director Youngchae Jeon
Comments0